Condition: TMB-H · Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors · Sponsor: ImmuneOncia Therapeutics Inc.
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
This description comes directly from the study's public registry record.
SUNGYOUNG LEE · +82 2 6283 5096 · sylee@immuneoncia.com
Always discuss trial participation with your own doctor first.
| National Cancer Center | Goyang, South Korea | Recruiting |
| Seoul National University Bundang Hospital | Seongnam, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06365840